Market Overview:
The global orally disintegrating tablet market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and technological advancements in orally disintegrating tablets. Based on type, the global orally disintegrating tablet market is segmented into anti-psychotics drug, anti-epileptics drug, and other types. The anti-psychotics drug segment is expected to account for the largest share of the global orally disintegrating tablet market in 2018. This segment is projected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030 due to increasing demand for these drugs for treating various psychiatric disorders such as schizophrenia and bipolar disorder. Based on application, the global orally disintegrating tablet market is divided into CNS diseases, gastrointestinal diseases, CV diseases, and other applications.
Product Definition:
An orally disintegrating tablet (ODT) is a drug delivery system that dissolves in the mouth, allowing the drug to be absorbed directly into the bloodstream. This type of tablet is often used for medications that are difficult to swallow, such as liquid medication or those with a bad taste.
Anti-Psychotics Drug:
Anti-psychotics drug is used to treat mental disorders such as schizophrenia, mania, and bipolar disorder. Anti-psychotics drugs are also used in the treatment of severe depression and anxiety disorders. The anti-psychotic drug works by blocking certain chemical transmissions in the brain leading to calming effect in patients suffering from these mental diseases.
Anti-Epileptics Drug:
An anti-epileptic drug is a medication used to prevent or reduce seizures. Anti-epileptic drugs are often called as antiseizure drugs. They can be classified into two types: first generation and second generation anti-epileptics. The most common type of these drugs is Carbamazepine (Tegretol).
Application Insights:
CNS diseases accounted for the largest share in 2015 owing to the high prevalence of epilepsy and Alzheimer¢â‚¬â„¢s disease. The other application segment, which includes cardiovascular diseases, respiratory disorders, gastrointestinal diseases and others is expected to witness significant growth during the forecast period due to increasing product usage in these conditions.
The gastrointestinal disorders segment is anticipated to exhibit rapid growth over the forecast period owing to growing awareness about better treatment options for irritable bowel syndrome and Crohn¢â‚¬â„¢s disease. Furthermore, there are a number of drugs available only as ODT that have shown positive results in clinical trials which will further boost market growth during this study period. However, competition from generic drugs may pose a threat towards market penetration over the next few years.
Regional Analysis:
North America dominated the global market in 2017. The presence of key manufacturers and well-established healthcare infrastructure are some of the factors responsible for its large share. Furthermore, rising incidence rates of various neurological, gastrointestinal (GI), and central nervous system (CNS) diseases are expected to drive product demand over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to increasing disposable income levels, growing awareness about mental health issues among consumers, increased availability & accessibility of quality treatment options along with a high prevalence rate for neurodegenerative conditions such as Parkinson’s disease or Alzheimer's disease is anticipated to fuel market growth in this region over next eight years.
Europe accounted for more than 20% share in terms of revenue.
Growth Factors:
- Increasing geriatric population: The global geriatric population is expected to grow at a CAGR of 6.5% from 2016 to 2020, owing to the increase in life expectancy and the growth in the number of people aged 65 years and above. This will result in an increase in demand for ODTs, as they are easier for elderly people to consume than tablets or capsules.
- Rise in chronic diseases: The prevalence of chronic diseases such as diabetes, cancer, and Alzheimer’s is increasing globally, which is leading to an increased demand for medications that can be easily administered orally. ODTs are ideal for this purpose as they dissolve quickly and do not require water or swallowing whole pills like traditional tablets do.
- Technological advancements: The development of new technologies such as taste-masking agents and modified-release formulations has helped improve the efficacy and patient compliance with ODTs products over traditional oral medications. This is likely to drive market growth over the next few years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Orally Disintegrating Tablet Market Research Report
By Type
Anti-Psychotics Drug, Anti-Epileptics Drug, Other
By Application
CNS Diseases, Gastrointestinal Diseases, CVS Diseases, Other
By Companies
GSK, Otsuka, Mylan, Teva, Pfizer, Eli Lilly and Company, Merck, Eisai, AstraZeneca, Bristol-Myers Squibb, Conquer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Orally Disintegrating Tablet Market Report Segments:
The global Orally Disintegrating Tablet market is segmented on the basis of:
Types
Anti-Psychotics Drug, Anti-Epileptics Drug, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
CNS Diseases, Gastrointestinal Diseases, CVS Diseases, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GSK
- Otsuka
- Mylan
- Teva
- Pfizer
- Eli Lilly and Company
- Merck
- Eisai
- AstraZeneca
- Bristol-Myers Squibb
- Conquer
Highlights of The Orally Disintegrating Tablet Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-Psychotics Drug
- Anti-Epileptics Drug
- Other
- By Application:
- CNS Diseases
- Gastrointestinal Diseases
- CVS Diseases
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Orally Disintegrating Tablet Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Orally disintegrating tablets are a type of medication that is taken by mouth. They work by breaking down in the stomach and intestines, which helps to eliminate the drug from the body.
Some of the major companies in the orally disintegrating tablet market are GSK, Otsuka, Mylan, Teva, Pfizer, Eli Lilly and Company, Merck, Eisai, AstraZeneca, Bristol-Myers Squibb, Conquer.
The orally disintegrating tablet market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Orally Disintegrating Tablet Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Orally Disintegrating Tablet Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Orally Disintegrating Tablet Market - Supply Chain
4.5. Global Orally Disintegrating Tablet Market Forecast
4.5.1. Orally Disintegrating Tablet Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Orally Disintegrating Tablet Market Size (000 Units) and Y-o-Y Growth
4.5.3. Orally Disintegrating Tablet Market Absolute $ Opportunity
5. Global Orally Disintegrating Tablet Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Orally Disintegrating Tablet Market Size and Volume Forecast by Type
5.3.1. Anti-Psychotics Drug
5.3.2. Anti-Epileptics Drug
5.3.3. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Orally Disintegrating Tablet Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Orally Disintegrating Tablet Market Size and Volume Forecast by Application
6.3.1. CNS Diseases
6.3.2. Gastrointestinal Diseases
6.3.3. CVS Diseases
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Orally Disintegrating Tablet Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Orally Disintegrating Tablet Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Orally Disintegrating Tablet Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Orally Disintegrating Tablet Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Orally Disintegrating Tablet Demand Share Forecast, 2019-2026
9. North America Orally Disintegrating Tablet Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Orally Disintegrating Tablet Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Orally Disintegrating Tablet Market Size and Volume Forecast by Application
9.4.1. CNS Diseases
9.4.2. Gastrointestinal Diseases
9.4.3. CVS Diseases
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Orally Disintegrating Tablet Market Size and Volume Forecast by Type
9.7.1. Anti-Psychotics Drug
9.7.2. Anti-Epileptics Drug
9.7.3. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Orally Disintegrating Tablet Demand Share Forecast, 2019-2026
10. Latin America Orally Disintegrating Tablet Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Orally Disintegrating Tablet Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Orally Disintegrating Tablet Market Size and Volume Forecast by Application
10.4.1. CNS Diseases
10.4.2. Gastrointestinal Diseases
10.4.3. CVS Diseases
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Orally Disintegrating Tablet Market Size and Volume Forecast by Type
10.7.1. Anti-Psychotics Drug
10.7.2. Anti-Epileptics Drug
10.7.3. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Orally Disintegrating Tablet Demand Share Forecast, 2019-2026
11. Europe Orally Disintegrating Tablet Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Orally Disintegrating Tablet Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Orally Disintegrating Tablet Market Size and Volume Forecast by Application
11.4.1. CNS Diseases
11.4.2. Gastrointestinal Diseases
11.4.3. CVS Diseases
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Orally Disintegrating Tablet Market Size and Volume Forecast by Type
11.7.1. Anti-Psychotics Drug
11.7.. Anti-Epileptics Drug
11.7.3. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Orally Disintegrating Tablet Demand Share, 2019-2026
12. Asia Pacific Orally Disintegrating Tablet Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Orally Disintegrating Tablet Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Orally Disintegrating Tablet Market Size and Volume Forecast by Application
12.4.1. CNS Diseases
12.4.2. Gastrointestinal Diseases
12.4.3. CVS Diseases
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Orally Disintegrating Tablet Market Size and Volume Forecast by Type
12.7.1. Anti-Psychotics Drug
12.7.2. Anti-Epileptics Drug
12.7.3. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Orally Disintegrating Tablet Demand Share, 2019-2026
13. Middle East & Africa Orally Disintegrating Tablet Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Orally Disintegrating Tablet Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Orally Disintegrating Tablet Market Size and Volume Forecast by Application
13.4.1. CNS Diseases
13.4.2. Gastrointestinal Diseases
13.4.3. CVS Diseases
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Orally Disintegrating Tablet Market Size and Volume Forecast by Type
13.7.1. Anti-Psychotics Drug
13.7.2. Anti-Epileptics Drug
13.7.3. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Orally Disintegrating Tablet Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Orally Disintegrating Tablet Market: Market Share Analysis
14.2. Orally Disintegrating Tablet Distributors and Customers
14.3. Orally Disintegrating Tablet Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GSK
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Otsuka
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Mylan
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Teva
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Pfizer
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Eli Lilly and Company
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Merck
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Eisai
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. AstraZeneca
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Bristol-Myers Squibb
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Conquer
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
